Search academic texts

Information × Registration Number 0215U001642, 0112U000007 , R & D reports Title To develop methods of pathogenetic therapy of patients with limited scleroderma and chronic lupus erythematosus with the morphological changes of the skin, the immune system and connective tissue metabolism popup.stage_title Head Kutasevych Yanina Francivna, Registration Date 09-04-2015 Organization Ukranian research institute of dermatology and venerology popup.description2 The object of study: limited scleroderma and chronic lupus erythematosus. The aim of the study was to increase the effectiveness of treatment of patients with autoimmune connective tissue diseases, mainly affecting the skin (limited scleroderma and chronic lupus erythematosus), subject to certain morphological, immunomorphological, immunohistochemical disorders, especially of collagen, the immune status of patients and metabolic disorders, including skin, bacteriological studies. Methods: сlinical, biochemical, biophysical, bacteriological, immunological, molecular genetic, statistics. Clinical features for a limited scleroderma and chronic lupus erythematosus was defined at the present stage. The relationship between single nucleotide polymorphism rs7574865 gene STAT4 and the development of chronic lupus erythematosus and scleroderma was established. Hormones imbalance of patients with limited scleroderma established to compose in lowering testosterone, progesterone and estradiol in men, progesterone and estradiol in females. Elucidated the dynamics of morphological and functional changes of collagen and immunological disorders in the skin of patients with the disease stage. Characterized by immunological abnormalities in patients. It is shown that dysbiosis nasopharynx were observed in the groups of patients with moderate and severe course of these diseases with the possible formation of associations of several species of streptococci. Through the application of remote thermography to determine the activity of connective tissue inflammation and sclerosis lesions in patients with limited scleroderma. A complex pathogenetic treatment of patients with limited scleroderma with the appointment of an anti-inflammatory anti-fibrotic drug penicillin G and metabolic means: glutargin and magnerot. A complex pathogenetic treatment of patients with chronic lupus erythematosus with the appointment of an anti-inflammatory and immunomodulating drug dapsone metabolic means: glutargin and magnerot. The positive influence of the developed methods of treatment on the clinical course of dermatoses, immune status, purine, connective exchanges and other key indicators of homeostasis. Product Description popup.authors Іванова Ніна Миколаївна Білозоров Олексій Павлович Болотна Людмила Анатоліївна Волкославська Валентина Миколаївна Джораєва Світлана Кар'ягдиївна Земляна Тетяна Вікторівна Кутасевич Яніна Францівна Левицька Олена Володимирівна Мілютина Олена Йосипівна Маштакова Ірина Олексіївна Олійник Ірина Олександрівна П'ятикоп Інна Олександрівна Савенкова Вікторія Володимирівна Семко Галина Олександрівна Сокол Оксана Анатоліївна Солошенко Ельвіра Миколаївна Частій Тетяна Володимирівна Шевченко Зоя Михайлівна Юхимчук Євгеній Володимирович Ярмак Тетяна Павлівна popup.nrat_date 2020-04-02 Close